A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial by Arturo Chang-Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Consuelo Macías-Abraham, Laura Rodríguez-Noda, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María de los Ángeles García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Dairon Rodríguez-Prieto, Rinaldo Puga-Gómez, Pedro Pablo Guerra-Chaviano, Yaíma Zúñiga-Rosales, Beatriz Marcheco-Teruel, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Delia Porto-González, Olivia Fernández-Medina, Anet Valdés-Zayas, Guang-Wu Chen, Luís Herrera-Martínez, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Verez-Bencomo

Connect to this object online.